Japan's Kyowa Kirin reorganizes quality responsibilities 

Japan's Kyowa Kirin has set in motion changes to its quality assurance. (Kyowa Kirin)

Japan’s Kyowa Kirin, which recently won approval in the U.S. of a drug for Parkinson’s disease, says it is putting quality assurance and pharmacovigilance front and center. 

Under a company reorganization that takes effect Jan. 1, the company has created quality and pharmacovigilance divisions that will report directly to the CEO, Kyowa Kirin announced (PDF) today. 

RELATED: Spurned by FDA a decade ago, Kyowa Kirin wins nod for Parkinson's drug

On-Demand Webinar

Leveraging A Medical Record-Enriched Patient Dataset for COVID-19 Research

You are invited to join a webinar that will explore the ways researchers can leverage this enriched dataset for important COVID-19 research. Sign up today for this informative webinar to learn how you can leverage one of the only medical record reviews solely using real-world data from hospitalized COVID-19 patients.

As part of the reorg, it is establishing quality assurance and regulatory audit departments that will be part of the quality division. It said the changes were made to clarify roles and responsibilities and to pursue maintenance and improve the quality of the drugs it makes.

The changes come three months after Kyowa Kirin won FDA approval of Nourianz, which had been rejected by the FDA more than a decade ago. The drug has been sold in Japan since 2013 but was turned away by the FDA in 2008 over concerns about its efficacy. 

RELATED: Japanese API maker Kyowa Hakko Bio admits manipulating testing data

Last year, another unit of Kirin Holdings, Kyowa Hakko Bio, had a plant in Yamaguchi, Japan, slapped with a warning letter after managers acknowledged workers manipulated data to get passing results when out-of-specification results appeared during testing. 

Suggested Articles

Life sciences companies have pivoted quickly during COVID-19 - Syneos Health® is supporting more than 80 active COVID-19 projects, including vaccines.

New York's Covaxx has signed on with three South American nations to provide 140 million doses of its early-stage COVID-19 vaccine.

To get the COVID-19 vaccine out quickly, Pfizer has been running rehearsals at distribution sites, creating "growing confidence," U.S. officials said.